Patient characteristics for MER cohort
| . | All FL . | OBS/rituximab monotherapy . | Chemotherapy treated . |
|---|---|---|---|
| . | (N = 209) . | (N = 103) . | (N = 81) . |
| Age, median (range) | 59 (23-93) | 61 (23-84) | 56 (28-93) |
| Male | 112 (54%) | 51 (50%) | 44 (54%) |
| Age >60 | 93 (45%) | 53 (51%) | 28 (35%) |
| PS 2+ | 4 (2%) | 0 (0%) | 4 (5%) |
| Ann Arbor stage III/IV | 147 (71%) | 75 (74%) | 67 (83%) |
| 2+ Extranodal sites | 6 (3%) | 0 (0%) | 5 (6%) |
| LDH > ULN | 36 (18%) | 18 (18%) | 15 (19%) |
| B symptoms | 13 (6%) | 4 (4%) | 9 (11%) |
| BM involvement | 86 (41%) | 42 (41%) | 41 (50%) |
| HGB <12 | 14 (7%) | 7 (7%) | 7 (9%) |
| >4 Nodal areas | 76 (37%) | 39 (38%) | 35 (43%) |
| FLIPI | |||
| 0-1 | 91 (43%) | 39 (38%) | 31 (38%) |
| 2 | 65 (31%) | 34 (33%) | 29 (36%) |
| 3-5 | 53 (26%) | 30 (29%) | 21 (26%) |
| Initial therapy | |||
| Observation | 73 (35%) | 73 (71%) | 0 |
| Rituximab monotherapy | 30 (14%) | 30 (29%) | 0 |
| Alkylator-based chemotherapy | 46 (22%) | 0 | 46 (57%) |
| Anthracyline-based chemotherapy | 35 (17%) | 0 | 35 (43%) |
| Other therapy | 24 (12%) | 0 | 0 |
| Grade | |||
| 1-2 | 180 (86%) | 100 (97%) | 56 (69%) |
| 3a | 29 (14%) | 3 (3%) | 25 (31%) |
| Events | 120 (57%) | 77 (75%) | 38 (47%) |
| Deaths | 23 (11%) | 12 (12%) | 9 (11%) |
| . | All FL . | OBS/rituximab monotherapy . | Chemotherapy treated . |
|---|---|---|---|
| . | (N = 209) . | (N = 103) . | (N = 81) . |
| Age, median (range) | 59 (23-93) | 61 (23-84) | 56 (28-93) |
| Male | 112 (54%) | 51 (50%) | 44 (54%) |
| Age >60 | 93 (45%) | 53 (51%) | 28 (35%) |
| PS 2+ | 4 (2%) | 0 (0%) | 4 (5%) |
| Ann Arbor stage III/IV | 147 (71%) | 75 (74%) | 67 (83%) |
| 2+ Extranodal sites | 6 (3%) | 0 (0%) | 5 (6%) |
| LDH > ULN | 36 (18%) | 18 (18%) | 15 (19%) |
| B symptoms | 13 (6%) | 4 (4%) | 9 (11%) |
| BM involvement | 86 (41%) | 42 (41%) | 41 (50%) |
| HGB <12 | 14 (7%) | 7 (7%) | 7 (9%) |
| >4 Nodal areas | 76 (37%) | 39 (38%) | 35 (43%) |
| FLIPI | |||
| 0-1 | 91 (43%) | 39 (38%) | 31 (38%) |
| 2 | 65 (31%) | 34 (33%) | 29 (36%) |
| 3-5 | 53 (26%) | 30 (29%) | 21 (26%) |
| Initial therapy | |||
| Observation | 73 (35%) | 73 (71%) | 0 |
| Rituximab monotherapy | 30 (14%) | 30 (29%) | 0 |
| Alkylator-based chemotherapy | 46 (22%) | 0 | 46 (57%) |
| Anthracyline-based chemotherapy | 35 (17%) | 0 | 35 (43%) |
| Other therapy | 24 (12%) | 0 | 0 |
| Grade | |||
| 1-2 | 180 (86%) | 100 (97%) | 56 (69%) |
| 3a | 29 (14%) | 3 (3%) | 25 (31%) |
| Events | 120 (57%) | 77 (75%) | 38 (47%) |
| Deaths | 23 (11%) | 12 (12%) | 9 (11%) |
BM, bone marrow; LDH, lactate dehydrogenase; OBS, observation; ULN, upper limit of normal.